SCCT 2024: HeartFlow to Present New Data on Coronary Artery Disease Management with Coronary Computed Tomography Angiography
16 juil. 2024 12h00 HE
|
HeartFlow Holding, Inc.
MOUNTAIN VIEW, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- HeartFlow, a leader in non-invasive artificial intelligence (AI) heart care solutions, today announced it will be presenting new findings on...
OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101
11 juil. 2024 07h00 HE
|
OKYO Pharma LTD
Phase 2 randomized, placebo-controlled trial in neuropathic corneal pain (NCP) patients planned to begin in Q3, 2024OK-101 is believed to be the first IND clearance granted by FDA for a drug to begin...
Kymera Announces Expansion of KT-474 (SAR444656) HS and AD Phase 2 Studies Following Interim Review of Safety and Efficacy
08 juil. 2024 16h05 HE
|
Kymera Therapeutics, Inc.
WATERTOWN, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using...
Forbion Strengthens US Presence, Hiring Biotech Industry Leader and Opening Boston Office
27 juin 2024 07h00 HE
|
Forbion
Josh Brumm, previously CEO of Dyne Therapeutics, appointed as General Partner at Forbion. Brumm to be located at Forbion's new Boston office.
Kymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting
14 juin 2024 07h00 HE
|
Kymera Therapeutics, Inc.
KT-333 demonstrated initial clinical proof of concept across multiple hematological malignancies, including complete responses in two patients with Hodgkin’s lymphoma Robust STAT3 knockdown and...
Neurona Therapeutics Appoints Dr. Manher Joshi as Chief Medical Officer
11 juin 2024 16h05 HE
|
Neurona Therapeutics
Neurona Therapeutics Appoints Dr. Manher Joshi as Chief Medical Officer
WellSpan Health Partners with Jersey College to Establish a Dedicated School of Nursing in South Central Pennsylvania
11 juin 2024 09h41 HE
|
WellSpan Health
York, Pa., June 11, 2024 (GLOBE NEWSWIRE) -- WellSpan Health and Jersey College, an accredited post-secondary institution specializing in nursing education, have received regulatory approval to...
Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
01 juin 2024 08h00 HE
|
Kymera Therapeutics, Inc.
KT-253 demonstrates initial clinical proof of concept in patients with tumor types shown to be sensitive in preclinical models, including responses in MCC and AML Evidence of target engagement...
Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
23 mai 2024 17h00 HE
|
Kymera Therapeutics, Inc.
Abstract released today highlights safety, pharmacodynamic and clinical response data with additional data to be presented in a poster session on June 1, 2024 KT-253 Phase 1 study ongoing with...
A Bold Step Forward: Trial Equity and Miller Tanner Associates Partner to Champion Diversity in Clinical Research
22 mai 2024 10h23 HE
|
Trial Equity
Trial Equity and Miller Tanner Associates are partnering to expand clinical trial participation to address the gap in diversity.